Exhibit 10.21
This document, when properly executed, shall constitute a Supply Agreement
between Progenics Pharmaceuticals, Inc. with offices at Old Saw Mill River Road,
Tarrytown, NY, (Progenics) and E.I. Du Pont de Nemours and Company (Du Pont),
with offices at 000 Xxxxxx Xxxxxx, Xxxxxx, XX.
1. PERIOD OF AGREEMENT: July 1, 1993 through June 30, 1996. After the
original term, this Agreement will renew automatically for successive 12 month
periods unless either party gives notice to the other of its intention not to
renew at least 120 days prior to the expiration of the then current term.
2. MATERIAL: Recombinant Soluble sCD4, referred to hereafter as sCD4 or
Product.
3. MATERIAL SPECIFICATIONS: Material shall be supplied in the form and
manner, and must conform in all material respects to the specifications set out
in Attachment A. Alterations to these specifications require the express
written consent of each party.
4. [***]
5. PAYMENT TERMS: Net 30 Days, following the receipt of a properly prepared
and correct invoice.
6. QUANTITY: Du Pont commits to purchase 100% of its purchase requirements
for sCD4 during the term of this order from Progenics, and Progenics agrees to
supply 100% of Du Pont's purchase requirements.
7. DELIVERY TERMS: F.O.B. Destination, freight collect.
8. RELEASES: Du Pont will advise Progenics of its purchase requirements at
least quarterly, or as may otherwise suit the parties by agreement. Progenics
shall ship product as required by Du Pont according to a mutually agreed upon
schedule. Progenics shall advise Du Pont at its earliest opportunity if it is
unable to ship Product at an agreed upon time. Progenics will, on a best effort
basis, attempt to fulfill any unscheduled, or spot requirements of Du Pont.
9. LABELLING AND PACKAGING: Both Du Pont's and Progenics' names and logos
shall appear on the main product label and on promotional literature, along with
the following statement: "Manufactured by Progenics Pharmaceuticals, Inc."
[***] Confidential Treatment Requested
-2-
All labels to be approved by both parties. All product labelling and literature
shall contain the phrase "For Laboratory Use." Progenics will package product
as 100 micrograms per vial, or in other package sizes as mutually agreed upon by
both parties. Product will be shipped on dry ice. In parallel, Progenics will
perform stability studies on lyophilized product. Shelf life of the sCD4 will
be no less than 6 months upon receipt by Du Pont.
10. CONFIDENTIALITY: The parties hereto shall keep confidential all
confidential technical information, shall not disclose or make known to any
individual, firm, or corporation, except when authorized in writing to do so by
the other party, and shall not use such information for any purpose other than
the performance of the obligations provided in this Agreement. The provisions
of this clause shall remain binding for five (5) years after the termination of
this agreement. Each party shall use the same degree of care to avoid
disclosure of confidential technical information as the party employs with
similar information of its own which it does not desire to publish or disclose.
Any confidential information shared between the parties must be identified and
labeled in writing as confidential. The confidentiality of and information
disclosed verbally must be identified in writing as confidential no more than 14
days after disclosure.
This obligation shall not apply to information and/or documents which:
A) Are or come within the public domain otherwise than as a consequence of a
breach of the obligations hereunder;
B) Are known to the receiving party prior to disclosure by the other party as
shown by the receiving party's records;
C) Are lawfully disclosed to the receiving party by third parties; or
D) Are subsequently independently developed by the receiving party through no
reference whatsoever to disclosure hereunder.
11. WARRANTY: Progenics warrants the packaged product hereunder shall meet the
specifications set forth in Attachment A and shall be free from defects except
those caused by misuse or mishandling occurring after such delivery. Progenics
agrees to notify Du Pont prior to
-3-
making any formulation changes in the Product. Progenics further warrants that
packaged product will meet the warranty of merchantability and fitness for
intended use. In the event of a recall of Product, Progenics agrees to
reimburse Du Pont for all reasonable costs incurred in the recall.
12. USE OF MATERIAL: Progenics shall supply Du Pont sCD4 to be sold by Du Pont
to third parties. The material will be used only for research purposes and not
for other uses such as clinical diagnostics or therapeutic development. This
Agreement is limited to resale of sCD4 as packaged at Progenics and does not
allow Du Pont to modify sCD4 or combine sCD4 with other components.
[***]
[***] Confidential Treatment Requested
-4-
13. RELATIONSHIP OF THE PARTIES: Nothing contained herein shall be construed
to empower either party to act as agent for the other. The parties agree that
each of them shall, in relation to its obligations hereunder, be acting as an
independent contractor. Not withstanding, neither party shall, during the
period of this Agreement, enter into discussions nor create an alternative
arrangement with any third party concerning the subject matter herein, without
first advising the other party of its intent.
14. AUDITS: Progenics shall permit no less frequently than once per year, and
upon reasonable notice by Du Pont, inspections and audits by Du Pont during
regular business hours of all records and aspects of sCD4 manufacture, testing,
packaging, labeling and shipping.
15. CANCELLATIONS: This Agreement may be cancelled by either party upon 120
days written notice to the other party.
16. ENTIRETY: This Agreement, together with the Attachments specifically
referenced and attached hereto, embodies the entire understanding between Du
Pont and Progenics, and there are no contracts, warranties, or
representations, oral or written, express or implied, with reference to the
subject matter hereof which are not merged herein. Except as otherwise
specifically stated, no modification hereto shall be of any force or effect
unless reduced to writing and signed by both parties and expressly referred
to as being modifications of this Agreement.
AGREED & APPROVED:
FOR PROGENICS: FOR DU PONT:
Name Xxxx X. Xxxxxx, M.D., Ph.D. Name: Xxxxxx X. Hand
------------------------------- ------------------------------
Title Chairman and CEO Title: Senior Purchasing Agent
------------------------------ -----------------------------
Signature: /s/ Xxxx X. Xxxxxx Signature: /s/ Xxxxxx X. Hand
------------------------- -------------------------
Date: November 3, 1993 Date: October 27, 1993
------------------------------ ------------------------------
ATTACHMENT "A"
PRODUCT SPECIFICATION SHEET
PRODUCT: Recombinant Soluble CD4
PRODUCT Full-length extracellular domain of human CD4
DESCRIPTION: produced in a CHO expression system.
CONCENTRATION: GREATER THAN = 1.0 mg/ml
AMOUNT GREATER THAN = 100 micrograms/vial
STORAGE BUFFER: 50 mM MES, pH 6.0, 0.35M NaCl
SHIP: DRY ICE
STORE: -80 DEG. C
STABILITY: 6 months at -80 DEG. C
QUALITY CONTROL
CONCENTRATION Determined by Optical Density and
AND PURITY: SDS-PAGE/Silver stain (Purity GREATER THAN 95%)
AUTHENTICITY: Reactive with gp 120 and anti-CD4 monoclonal and
polyclonal antibodies.
Glycosylation pattern identical to natural
human product.
ACTIVITY: Binds HIV gp 120; inhibits binding of HIV to CD4+
lymphocytes and infection of CD4+ lymophoeytes with
HIV.
[LETTERHEAD]
Reference is made to the Agreement entered into the 3rd day of November, 1993,
as amended between NEN Life Science Products, a division of X.X. XxXxxx de
Nemours and Company (NEN) and Progenics Pharmaceuticals, Inc. (Progenics)
relative to the purchase of sCD4 by NEN. It is hereby mutually agreed to
further amend the aforesaid Agreement in the following manner effective July 1,
1996.
This amendment is being made to update pricing for a three year period as
follows:
[***]
All other terms and conditions of the current Agreement, except as modified in
the above manner, shall continue in full force and effect. Please indicate your
acceptance of this amendment by signing both copies in the space provided below
and return the copy marked "NEN M&L Copy" to Xxxx Xxxx-Xxxxxxx, X.X.XxXxxx de
Nemours and Company, Purchasing Department, 000 Xxxxxx Xxxxxx, Xxxxxx, XX 00000,
keeping the original for your files.
Very truly yours,
ProgensPharmaceuticals, Inc. NEN LIFE SCIENCE PRODUCTS
BY: BY: /s/ Xxxxxx X. Hand
TITLE: SR DIRECTOR, GRP. DEV. TITLE: Sr. Purchasing Agent
-----------------------------
DATE: June 26, 1996 DATE: June 13, 1996
------------------------------
[*** Confidential Treatment Requested]
